In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on DBV Technologies SA – American, with a price target of $40.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Fein has given his Buy rating due to a combination of factors, including DBV Technologies’ transition from a purely clinical story to one focused on execution and commercialization. He highlights that the company’s cash position of about $229M, with runway projected into 2Q27, supports the planned BLA submissions for the VIASKIN Peanut Patch in both children aged 4–7 and toddlers aged 1–3 during 2026, underpinning confidence in DBVT’s ability to reach the market.
Fein also points to the strong Phase 3 data in the 4–7 age group and growing physician enthusiasm observed at recent allergy meetings as key drivers of potential approval and adoption. He views the upcoming THRIVE Phase 2 trial in infants 6–12 months as a strategic expansion that could position VIASKIN not only as a safe option for accidental exposure protection but ultimately as a preferred immunotherapy enabling dietary peanut intake, and he maintains an unchanged $40 price target reflecting this long-term commercial opportunity.
According to TipRanks, Fein is a 5-star analyst with an average return of 25.5% and a 55.06% success rate. Fein covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Wave Life Sciences, and Palvella Therapeutics.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $55.00 price target.